CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$166.97
+1.91% today
Updated 2026-04-30
Market cap
$8.23B
P/E ratio
—
P/S ratio
2.05x
EPS (TTM)
$-2.90
Dividend yield
—
52W range
$114 – $229
Volume
0.9M
Charles River Laboratories (CRL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-3.60%
Operating margin
4.51%
ROE
-4.23%
ROA
4.24%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.06B | $-55.78M | 38.42% | 17.78% | -5.27% |
| 2007 | $1.23B | $154.41M | 38.86% | 18.46% | 12.55% |
| 2008 | $1.34B | $-521.84M | 38.01% | -33.48% | -38.84% |
| 2009 | $1.20B | $114.44M | 35.17% | 14.10% | 9.52% |
| 2010 | $1.13B | $-336.67M | 33.95% | -26.34% | -29.70% |
| 2011 | $1.14B | $109.57M | 35.20% | 15.25% | 9.59% |
| 2012 | $1.13B | $97.30M | 34.71% | 14.68% | 8.61% |
| 2013 | $1.17B | $102.83M | 33.88% | 12.99% | 8.82% |
| 2014 | $1.30B | $126.70M | 36.42% | 13.69% | 9.76% |
| 2015 | $1.36B | $149.31M | 38.96% | 15.14% | 10.95% |
| 2016 | $1.68B | $154.76M | 38.30% | 14.13% | 9.20% |
| 2017 | $1.86B | $123.36M | 37.73% | 15.52% | 6.64% |
| 2018 | $2.27B | $226.37M | 37.07% | 14.62% | 9.99% |
| 2019 | $2.62B | $252.02M | 36.56% | 13.40% | 9.61% |
| 2020 | $2.92B | $364.30M | 36.72% | 14.80% | 12.46% |
| 2021 | $3.54B | $390.98M | 37.70% | 16.66% | 11.04% |
| 2022 | $3.98B | $486.23M | 36.79% | 16.37% | 12.23% |
| 2023 | $4.13B | $474.62M | 36.39% | 14.95% | 11.49% |
| 2024 | $4.05B | $10.30M | 32.88% | 5.61% | 0.25% |
| 2025 | $4.02B | $-144.34M | 30.52% | 12.65% | -3.59% |